Zimmer Biomet Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ivan Tornos
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 345 East Main Street Warsaw IN United States of America 46580
- IPO Date
- Jul 25, 2001
- CIK
- 0001136869
- Website
- zimmerbiomet.com
- Similar Companies
- Business
- Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products; sports medicine, biologics, and extremities technologies; surgical and precision instruments; dental implants; and bone cement products worldwide. Founded in 1927 and headquartered in Warsaw, Indiana, the company operates globally with approximately 17,000 employees across 31 offices, serving healthcare professionals and patients through innovative implants, digital technologies, robotics, and analytics that span the patient journey from pre- to post-operative care. Core offerings include the ROSA Robotics platform for imageless knee and hip procedures; knee systems such as Persona and Oxford; hip solutions like Avenir Complete and Arcos Modular Revision; foot and ankle products including A.L.P.S. plating systems and recent Gorilla Pilon Fusion Plating and Phantom TTC Trauma Nail; trauma fixation devices; sports medicine technologies like BioCUE and AperFix; dental reconstructive implants; and integrated digital tools such as mymobility platform and AI-driven navigation. Recent developments encompass the October 2025 completion of the Monogram Technologies acquisition, enhancing semi- and fully autonomous robotics capabilities; the Paragon 28 acquisition bolstering foot and ankle and SET business growth; FDA clearance in November 2025 for ROSA Knee with OptimiZe; launches of the Magnificent Seven product suite; and plans for smart implants, next-generation ROSA robotics in 2026, and 20 new SCT products, driving projected 3.5-4.5% revenue growth in 2025 amid U.S. commercial specialization and ASC channel expansion.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Zimmer Biomet: Does Slow And Steady Still Win The Race?
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Zimmer (ZBH) Up 3.1% Since Last Earnings Report: Can It Continue?
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
Why Zimmer Biomet (ZBH) is a Top Growth Stock for the Long-Term
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Cwm LLC Reduces Stock Position in Zimmer Biomet Holdings, Inc. $ZBH
These Analysts Slash Their Forecasts On Zimmer Biomet Following Q1 Results